AstraZeneca picks up Pfizer's rare disease gene therapies, taps new R&D leader as Mene Pangalos steps down - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
AstraZeneca’s Alexion subsidiary is snapping up a suite of Pfizer’s preclinical gene therapies in a move to expand its toolkit in rare disease R&D. The deal, which the companies said is worth up to $1 billion, was unveiled as AstraZeneca also announced that M…